
Arialys Therapeutics develops precision medicines blocking pathogenic brain autoantibodies for autoimmune neuropsychiatric disease as a precision-medicine company for that disease.
Arialys Therapeutics develops precision medicines blocking pathogenic brain autoantibodies, differentiated by structural analysis of receptor interactions. The company was founded to explore autoimmune neuropsychiatry and is a precision-medicine company for autoimmune neuropsychiatric disease.
Arialys uses structural analysis of autoantibody-NMDAR interactions to design precision medicine. Anti-NMDAR autoantibodies are detected across encephalitis, schizophrenia, dementia, stroke, and cancer-related cognitive impairment.

Aristea Therapeutics
aristeatx.com

Athos Therapeutics
athostx.com

APRINOIA Therapeutics
aprinoia.com

Libra Therapeutics

MindImmune Therapeutics
mindimmune.com

Alto Neuroscience

Allyx Therapeutics
allyxthera.com

Endlyz Therapeutics
endlyz.com

Neuron23
neuron23.com

Neurolixis
neurolixis.com
Plumeria Therapeutics

Halia Therapeutics
haliatx.com

Arkuda Therapeutics
arkudatx.com

Engrail Therapeutics
engrail.com

Psy Therapeutics
psythx.com

Ariel Precision Medicine
arielmedicine.com

Asylia Therapeutics
asyliatx.com

Lysosomal Therapeutics
lysosomaltx.com

Lusaris Therapeutics
lusaristx.com

Eumentis Therapeutics
Companies similar to Arialys Therapeutics include Aristea Therapeutics, Athos Therapeutics, APRINOIA Therapeutics and Libra Therapeutics.
Arialys Therapeutics was founded in 2021.
Arialys Therapeutics' headquarters is located in La Jolla, CA, US.
Arialys Therapeutics' most recent funding round was for $14.8M (USD) in June 2025.
As of Jun 13, 2025, Arialys Therapeutics has disclosed funding of $72.8M (USD).
Arialys Therapeutics has 5 employees as of Feb 5, 2024.